Navigation Links
Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors
Date:10/11/2010

AUSTIN, Texas, Oct. 11 /PRNewswire/ -- Apollo Endosurgery, Inc. announced completion of the first clinical case involving its FlexShears™ Endoscopic Scissors.  The new device was used to cut and remove an obstructing eroded suture from the patient's GI tract in a procedure that embodies the Apollo vision of improving patient care with flexible surgery.

The subject of the case had undergone a Roux-en-Y gastric bypass surgery in 2001, and subsequently had suffered from protracted obstructive symptoms.  A recent EGD performed to evaluate the patient's obstructive symptoms identified an eroded non-absorbable suture traversing the mid-lumen immediately distal to the gastric pouch as the probable cause.

"The thinking was that an open surgical procedure to remove the suture would be the likely next step," said the patient.

Wishing to avoid a subsequent surgery and the complications that can follow, the patient — himself a retired surgeon — began researching alternative therapies. An article in Obesity Surgery on the utility of endoscopic scissors in removing endolumenal sutures led the patient to the article's author, Dr. Subhas Banerjee, (Director of Endoscopy, Stanford Hospital) who was able treat the condition endoscopically.

The scissors used in prior suture removal cases conducted at Stanford were fragile and ill-suited to the application.  Aware of the pre-commercial availability of the FlexShears scissors — which incorporate novel blade technology and rotational ability — Dr. Banerjee contacted Apollo in preparation for the case.

Accessing the gastric pouch with a therapeutic gastroscope, the offending suture was readily identified and easily cut using the FlexShears scissors. In comments to Apollo's representative, Dr. Banerjee mentioned that the new scissors exceptional cutting ability and rotational capability provided a vast improvement over previous, similar devices. &
'/>"/>

SOURCE Apollo Endosurgery, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... ibrutinib may be effective and generally well-tolerated in patients ... separate study examining the safety and efficacy of ibrutinib ...
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
(Date:6/19/2013)... CCA , America's leader in partnership ... Vice President, Health Services, effective June 8, 2013. ... for CCA. He will replace the retiring Herb ... to lead CCA's dedicated team of health care professionals. ... and our partners as we provide effective care to ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Strict ... In July 2013, Orriant is launching a new ... and maintain compliance with regulations. New HHS ... receive wellness incentives if their employer offers outcome-based, ... have been compliant with these standards for nearly ...
(Date:6/19/2013)... Citi Bike has come to New York City ... Perna to know for sure how many patients will choose to ... have the option. In fact, he’s happy about anything that ... make it more convenient for them to visit his office at ... Complimentary Alternative Medicine at Back and Body Medical and an experienced ...
(Date:6/19/2013)... surgery have had a significant impact on survival ... injuries, including burns. Patients who survive the ... greatest risk from infections particularly the overwhelming, ... from inflammation-induced multiorgan failure. Now, a device ... measures the movement of key immune cells may ...
(Date:6/19/2013)... (June 19, 2013) The results of three important ... Neurosurgery , official journal of the Congress ... by Lippincott Williams & Wilkins , a part ... indicates that continuous "machine learning" using artificial neural networks ... patients with advanced brain cancers. Another study in the ...
Breaking Medicine News(10 mins):Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3
... leukemia, also shows promise against a type of stomach cancer ... a promising anti-leukemia drug for treatment of a relatively rare ... pill once a day, is effective in treating both forms ... cancer cells without attacking healthy cells and causing severe side ...
... mothers can modify the length of other women's menstrual ... mother - or their infants - made the cycles ... Ohio University.// ,She suggests this is due to ... as part of a human's desire to raise children ...
... Hopkins University School of Medicine have recently found that the ... that lets us stop smelling something, even though the odour ... issue of the journal Science show that a protein called ... job of these reurons is to detect smells and send ...
... immune cells which help protect us from disease does not ... it could be something to do with their shape. ... how immune cells behave in microgravity as part of their ... ,It has been found that astronauts have elevated virus levels ...
... The Federal Drug Administration approved OxyContin in late 1995 ... early 1996. Between that time and 2000, prescriptions for ... that they could get a powerful heroin-like high by ... powder.// ,Abuse of OxyContin, the nation's best ...
... Kava is derived from a leafy plant native to the ... implicated in approximately 25 cases of liver diseases. The herb ... to treat insomnia, anxiety, stress and muscle spasms. According to ... as// benzodiazepines but is not chemically related. ,Benzodiazepines have ...
Cached Medicine News:Health News:Immune cells halt round in space 2
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: